XOMA Raising $39.2M Publicly for Phase II Gevokizumab Trial
Less than two months after disclosing plans to trim its staff and kickstarting its commercial operations by in-licensing an approved hypertension drug, XOMA Corp. priced a public offering to raise about $39.2 million.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter